A randomized, placebo-controlled trial of aripiprazole for the treatment of methamphetamine dependence and associated psychosis.

Int J Psychiatry Clin Pract. 2012 Apr 10. [Epub ahead of print]


Sulaiman AH, Gill JS, Said MA, Zainal NZ, Hussein HM, Guan NC.


Department of Psychological Medicine, Faculty of Medicine, University Malaya , Kuala Lumpur , Malaysia.


OBJECTIVES: The objectives of this study were to determine the efficacy and safety of aripiprazole for treatment of psychosis, retention and abstinence in patients with methamphetamine dependence.

METHODS: This was a double-blind study where 37 methamphetamine dependent patients with history of psychosis were randomly assigned to receive aripiprazole (5-10 mg daily, N=19) or placebo (N=18) for 8 weeks. Follow-up evaluation was scheduled on day 7, 14, 28, 42 day 56 after enrolment.

RESULTS: Participants on aripiprazole were retained significantly longer in treatment (48.7 days, SD=4.0) compared to placebo (37.1 days, SD=5.0). The Kaplan-Meier survival analysis showed that participants on aripiprazole were less likely to drop out of the study than the placebo group (P=0.02, X(2) =5.3). Psychotic symptoms significantly decreased among those on aripiprazole as compared to placebo (P < 0.05). However, no statistically significance was found between the two groups in maintaining abstinence (generalised estimation equation (GEE) analysis, P = 0.41). No serious adverse events were reported in either group

CONCLUSIONS: Aripiprazole was no more effective than placebo in maintaining abstinence from methamphetamine use. However, it facilitated treatment retention and reduced the severity of psychotic symptoms. Aripiprazole was found to be generally safe and well tolerated.


  1. News
  2. Workshops & Short Courses
  3. Research
  4. Publication


The Occupational Medicine Clinic is a referral clinic for occupational diseases and is open on every Friday in University Malaya Medical Centre.